Cost-Effectiveness of Adjuvanted Influenza Vaccine in Older Adults in the Netherlands
The cost-effectiveness analysis of adjuvanted influenza vaccines (aIV) over standard vaccines (sIV) in older adults presents significant economic benefits, potentially reshaping market dynamics in the Netherlands. Pharma companies must adapt their marketing and reimbursement strategies to leverage these findings, particularly as they pertain to aging populations.
Signal
Cost-Effectiveness of Adjuvanted Influenza Vaccine in Older Adults in the Netherlands
Category
Strategy
Therapeutic Area
Infectious Disease / Influenza
Action
Monitor
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The cost-effectiveness analysis of adjuvanted influenza vaccines (aIV) over standard vaccines (sIV) in older adults presents significant economic benefits, potentially reshaping market dynamics in the Netherlands. Pharma companies must adapt their marketing and reimbursement strategies to leverage these findings, particularly as they pertain to aging populations.
Why it matters
The cost-effectiveness analysis of adjuvanted influenza vaccines (aIV) over standard vaccines (sIV) in older adults presents significant economic benefits, potentially reshaping market dynamics in the Netherlands. Pharma companies must adapt their marketing and reimbursement strategies to leverage these findings, particularly as they pertain to aging populations.
What changed
Other
Analysis
Replacing the standard influenza vaccine with the adjuvanted version in older adults could save €4.3-12.8 million and gain 2,220-6,659 QALYs.
The cost-effectiveness analysis of adjuvanted influenza vaccines (aIV) over standard vaccines (sIV) in older adults presents significant economic benefits, potentially reshaping market dynamics in the Netherlands. Pharma companies must adapt their marketing and reimbursement strategies to leverage these findings, particularly as they pertain to aging populations.
Monitor the Dutch Health Council's recommendations and any shifts in vaccine uptake among older adults following this analysis.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.